|
|
|
|
|
Table 9.1
Some Tumor Markers and Their Clinical Use |
|
|
|
|
| |
|
|
|
|
|
Carcinoembryonic antigen (CEA) |
|
|
|
| |
|
|
|
|
Various carcinomas: colorectal, breast, thyroid, prostate cancer; the most commonly used tumor marker |
|
|
|
|
| |
|
|
|
|
Nonmucinous ovarian carcinomas, various other carcinomas |
|
|
|
|
| |
|
|
|
|
Gastrointestinal and colorectal carcinomas |
|
|
|
|
| |
|
|
|
|
Metastatic breast cancer, ovarian cancer |
|
|
|
|
|
|
|
|
|
Prostatic acid phosphatase (PAP) |
|
|
|
| |
|
|
|
|
|
Prostate-specific antigen (PSA) |
|
|
|
| |
|
|
|
|
|
Ovarian cancer antigen (OCA) |
|
|
|
| |
|
|
|
|
|
Human chorionic gonadotropin (HCG) |
|
|
|
| |
|
|
|
|
Trophoblastic tumors, ovarian, breast, liver, lung carcinomas |
|
|
|
|
|
|
|
|
|
Plasminogen activators (PA) |
|
|
|
| |
| |
|
|
|
|
Bone tumors and bone metastases |
|
|
|
|
| |
|